Palvella expands QTORIN rapamycin program into angiokeratomas, plans Phase 2 in H2 2026

PALVELLA THERAPEUTICS, INC.

No FDA-approved therapies exist for clinically significant angiokeratomas, which affect >50,000 diagnosed U.S. patients.
Phase 2 trial of QTORIN rapamycin for angiokeratomas planned to start H2 2026; FDA meeting expected H1 2026.
Ongoing Phase 3 SELVA study for microcystic lymphatic malformations: top-line results Q1 2026; TOIVA Phase 2 results mid-Dec 2025.
Angiokeratomas recently classified as isolated lymphatic malformation by ISSVA in 2025.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.